Regulators Promote Early Process Understanding As Key To Success In Cell Therapy Manufacturing
US and Canadian regulators espouse the need for early – and deep – knowledge of cell and gene therapy products as they progress through the pipeline to commercialization. Not doing so compromises product quality, and increases risks to patients.
You may also be interested in...
Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.